Objective: Documentary retrieval and analysis of available evidence of drugs that may be used to treat novel coronavirus pneumonia (corona virus disease-19, COVID-19) to provide evidence-based medical basis for the treatment of the disease. Method: The computer retrieves PubMed, Clinic Trial.gov and the official website of the China Clinical Trials Registration Center to find research on the treatment of COVID-19. The literature screening is conducted independently by two researchers based on the criteria for inclusion and exclusion, and the final classification is summarized and analyzed according to the study drug category. Result: 2 case reports suggest that ridesivir, lopinavir, ritonavir and abidol may be used in COVID-19 treatment; but one small sample retrospective cohort study results suggest that the efficacy of lopinavir and abidol is not clear; in vitro studies, chloroquine and daranavir Severe acute respiratory syndrome coronavirus type 2 (severe Activity of acute respiratory syndrome coronavirus 2, sars-cov-2); the basis for ribavirin and interferon treatment of COVID-19 is primarily derived from the severe acute respiratory syndrome coronavirus (severe acute respiratory syndrome) Coronavirus, Sars-CoV) and the treatment of MERS-CoV (Middle East respiratory syndrome coronavirus, Mers-CoV). Currently, several randomized controlled trials to evaluate the efficacy and safety of the drug treatment COVID-19 are under way. Conclusion: Although the current antiviral treatment of COVID-19 is not supported by high-quality evidence-based medical evidence, several studies have been launched to evaluate the clinical efficacy of TCM and Western medicine treatment programs and will provide high-quality evidence support for COVID-19 treatment.

The new coronavirus pneumonia (COVID) -19 was officially named by the World Health Organization on February 11, 2020. COVID-19 viruses spread faster than acute respiratory syndrome coronavirus (SARS-CoV) and Middle Eastern respiratory syndrome coronavirus (MERSCOV) and human transmission [1-3]. COVID-19 is closely related to the bat-derived bat-sl-covzc45 and bat-sl-covzxc21, two severe acute respiratory syndrome coronaviruses. [1st paragraph]

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.

Objective To analyze 114 cases of suspected COVID-19 patients, explore the value of multiple virus detection in outbreak prevention control by using Real Time RTGPCR technology to detect Sars-COV-2 nucleic acid in patients suspected in hot patients with COVID-19, using gene chip thermostat amplification technology to detect SarS-COV-2 nucleic acid 18 other common respiratory viruses in negative patients. Results 114 cases of COVID-19 suspected patients Sars-Cov-2 nucleic acid were negative, 21 cases were infected with non-other respiratory viruses, an infection rate of 18.42%, a total of 10 respiratory viruses were detected in 21 patients, including coronavirus NL63/229, respiratory syncytial virus, Ke. Saatchi virus type A16 , influenza B virus, human parinfluenza virus type 1, human parinfluenza virus type 3, human parinfluenza virus, influenza A virus seasonal H3 subtype, enterovirus/rhinovirus. Infection with 2 viruses: Respiratory syncytial virus and Cosache virus type A16, coronavirus NL63/229 mixed with human para-influenza virus type 1, influenza A virus with influenza A virus seasonal H3 subtype infection. Conclusion In response to this Sars-Cov-2 outbreak, care should be taken to identify Sars-Cov-2 and other respiratory viruses in a timely and effective manner to exclude suspected cases..

OBJECTIVE: Review of the evidence on the psychosocial impact of quarantine measures during serious coronavirus outbreaks before COVID-19. Such information is highly relevant in regard to the COVID-19 pandemic. METHODS: Search of the MEDLINE database for relevant studies related to SARS-CoV and MERS-CoV outbreaks. RESULTS: Across 13 identified studies, quarantine measures were consistently associated with negative psychosocial outcomes, including depressive symptoms, anxiety, anger, stress, posttraumatic stress, social isolation, loneliness and stigmatization. Determinants comprised duration of quarantine measures and income losses. Health care workers constituted a particularly vulnerable group. CONCLUSION: Quarantine measures during serious coronavirus outbreaks have extensive negative consequences for mental health. Prevention and intervention approaches to attenuate the psychosocial impact should be an integral component of crisis response during pandemic conditions.

OBJECTIVE: To investigate the value of serum-specific antibody of 2019 novel coronavirus(2019-nCoV) in the diagnosis of Coronavirus Disease 2019(COVID-19).METHODS: The plasma samples of236 confirmed and 79 suspected patients with COVID-19 were detected by immunochromatography assays for 2019-nCoV total antibodies and IgM/IgG antibodies.The nucleic acids were detected by real-time fluorescent quantitative PCR.RESULTS: In the confirmed group of 236 cases, the positive rates of the two detection reagents were 86.02%(203/236) and 84.32%(199/236); Among the 79 suspected cases, the positive rates of the two agents were 78.48%(62/79) and 70.89%(56/79).The sensitivity, specificity, positive value(PPV), negative predictive value(NPV) and compliance rates of the two reagents were 86.02% and 84.32%, 96.61% and 96.61%, 99.02% and 99.00%,63.33% and 60.64%, 88.14% and 86.78%, respectively.There was no significant difference in the detection efficacy between the two reagents by statistical analysis(P>0.05).The positive rates of IgM and IgG were 73.31%(173/236) and 85.59%(202/236) in the COVID-19 confirmed group,and 12.66%(10/79) and 65.82%(52/79) in COVID-19 suspected group, respectively.There was a statistically significant difference in IgM positive rates between the two groups(P<0.01).CONCLUSION: Serum-specific antibody could be used as a valued index to evaluate 2019-nCoV infection, and IgM is efficient for the diagnosing and excluding the COVID-19 patients with negative nucleic acid tests.

OBJECTIVE: To evaluate the efficacy and safety of ribavirin for COVID-19 by systematically reviewing previous clinical studies of coronavirus pneumonia. METHODS: Such databases as Pubmed, EMbase, Cochrane Library, Google Scholar, CNKI, Wanfang Data, VIP and CBM were searched. The date of the latest search was April 29, 2020. Clinical studies on ribavirin used in the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) were included. The literature was screened according to the inclusion and exclusion criteria and the methodological quality of the included studies was assessed by two reviewers independently. Meta-analysis was performed using Review Manager 5.3 software. RESULTS: In total, 7 studies were included, resulting in a sample size of 870 cases. The overall pooled data demonstrated that the difference in mortality rates between the ribavirin group and control group was not statistically significant in the treatment of SARS and MERS[OR=1.10,95％CI（0.79,1.55）,P=0.57]. In the subgroup analysis, the mortality rate was not significantly different between the ribavirin group and control group in the treatment of SARS and MERS whether ribavirin was combined with interferon or not. CONCLUSION: Ribavirin does not make much difference to mortality in the treatment of SARS and MERS, but it can increase drug safety risks. Thus, the applicability of ribavirin in the treatment of COVID-19 remains to be investigated

Objective To explore the application of different detection methods for IgM and IgG antibodies of new coronavirus (SARS-CoV-2) in 2019 coronavirus disease (COVID-19). Methods Twenty-five patients with COVID-19 were selected, and 20 patients who were excluded from SARS-CoV-2 infection during the same period were used as the control group. Serum SARS-CoV-2 IgM and IgG were detected by magnetic particle chemiluminescence method and colloidal gold method respectively. antibody. Simultaneous detection of serum procalcitonin (PCT), ferritin and C-reactive protein (CRP) in patients with COVID-19. Results The sensitivity of the chemiluminescence method to detect serum SARS-CoV-2 IgM and IgG antibodies was 48% and 56%, and the specificity was 100%. The colloidal gold method was used to detect the sensitivity of serum SARS-CoV-2 IgM and IgG antibodies. They were 88% and 76%, respectively, and the clinical specificity was 100%. The two methods used to detect the serum SARS-CoV-2 IgM and IgG antibodies were 68.9% and 73.3% respectively. Of the 25 COVID-19 patients, 36% had elevated serum PCT, 72% had elevated serum CRP, and 84% had elevated serum ferritin. Conclusion　The detection methods of SARS-CoV-2 IgM and IgG antibodies are quite different, and should be considered comprehensively when used in the clinical diagnosis of COVID-19 patients.

Objective To study novel coronavirus (SARS? CoV? 2) Nucleic acid gene detection and its imaging control. method of real-time fluorescence RT? PCR method detecting SARS? CoV? 2 orf1a/b and N genes, analyzed 23 cases of SARS? CoV? 2 Clinical and imaging data of patients with positive nucleic acid. Results ① 3 cases of asymptomatic infections, COVID? 19 confirmed 20 cases, 2 to 24 days incubation period, 5 cases of adult light, 1 case of child light, 1 case of young person, 13 cases of adult general type. CoV? 2 genetically positive patients, sputum specimens have higher viral content and detection effects than nasopharyngeal swabs specimens, N gene feces longer than phlegm and nasopharyngeal swab positive duration. 30.0% (6/20) CT scans did not see abnormalities. Viral load and imaging correspond unproportionally to peripheral band (13/14) and posterior basal segment of the lower lobe (11/14), involvement of two or more pulmonary lobes (11/14), bilateral lesions (11/14) .14 CT abnormal COVID? In 19, imaging is mainly shown by gross glass shadow (10/14), double lung flake shadow (10/14), halo sign (8/14), fine mesh sign (5/14), and thickening with lobe intervals (5/14), bronchial inflatable signs (5/14), and small vascular thickening (5/14). Relationship, sars? CoV? 2 Nucleic acid detection combined with CT scan, epidemiological history can improve COVID? 19, can not be relied on solely on nucleic acid PCR or CT tests.

OBJECTIVES: To investigate imaging features of the coronavirus disease 2019 (COVID-19), and to provide concrete evidences for diagnosis of COVID-19. METHODS: Imaging data of the first chest CT examination and clinical data (age, sex, clinical history, epidemiological history, and laboratory tests) of 163 patients with COVID-19 from 2 hospitals were collected for retrospective analysis. Imaging features of the first chest CT examination and the correspondence between CT manifestations and the nucleic acid test results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were analyzed. RESULTS: The first chest CT images of 163 COVID-19 patients showed that 92.02% of lesions were ground-glass opacity (GGO), 76.69% were consolidation, and 73.62% were GGO together with consolidation. Multiple lesions were found in 71.17% patients and multiple lobules in 86.50% patients. Lesions in 53.37% patients were found with bronchial inflation signs and those in 36.20% patients presented with "crazy paving" pattern, while only 7.36% were found with hilar node enlargement and pleural effusion. First CT findings of 18 patients were found to be inconsistent with the results of pathogen examination. CONCLUSIONS: COVID-19 patients showed specific features in the first chest CT examination. The combination of the first chest CT imaging features and SARS-CoV-2 nucleic acid test results as well as reexamination if necessary can help to make the diagnosis of SARS-CoV-2 infection accurately.